QiShenYiQi Attenuates Renal Interstitial Fibrosis by Blocking the Activation of β-Catenin

Chronic kidney disease (CKD) is becoming a worldwide problem. However, current treatment options are limited. In the current study we showed that QiShenYiQi (QSYQ), a water-ethanol extract from several Chinese medicines, is a potent inhibitor of renal interstitial fibrosis. QSYQ inhibited transformi...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2016-09, Vol.11 (9), p.e0162873
Main Authors: Zhou, Zhanmei, Hu, Zheng, Li, Mei, Zhu, Fengxin, Zhang, Hao, Nie, Jing, Ai, Jun
Format: Article
Language:English
Subjects:
Actin
Actins - antagonists & inhibitors
Animals
beta Catenin - metabolism
Biology and Life Sciences
Collagen
Collagen (type I)
Diabetes
Drugs, Chinese Herbal - therapeutic use
Ethanol
Experiments
Extracellular matrix
FDA approval
Fibroblasts
Fibronectin
Fibrosis
Fibrosis - drug therapy
Gene expression
Gene regulation
Growth factors
Herbal medicine
Hospitals
Kidney diseases
Kinases
Laboratory animals
Male
Medical research
Medicine and Health Sciences
Metabolism
Muscles
Nephrology
Nephropathy
Physical Sciences
R&D
Rats
Rats, Sprague-Dawley
Renal Insufficiency, Chronic - drug therapy
Research & development
Research and Analysis Methods
Rodents
Smooth muscle
Transcription
Transcription, Genetic
Transforming growth factor
Transforming Growth Factor beta1 - physiology
Transforming growth factor-b1
β-Catenin
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Chronic kidney disease (CKD) is becoming a worldwide problem. However, current treatment options are limited. In the current study we showed that QiShenYiQi (QSYQ), a water-ethanol extract from several Chinese medicines, is a potent inhibitor of renal interstitial fibrosis. QSYQ inhibited transforming growth factor-β1 (TGF-β1)-responsive α-smooth muscle actin (α-SMA), collagen I, and fibronectin up-regulation in obstructive nephropathy and cultured cells. Administration of QSYQ also inhibited the established renal interstitial fibrosis in obstructive nephropathy. Interestingly, QSYQ selectively inhibited TGF-β1-induced β-catenin up-regulation and downstream gene transcription. Taken together, our study suggests that QSYQ selectively inhibits TGF-β1-induced β-catenin up-regulation and might have significant therapeutic potential for the treatment of renal fibrosis.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0162873